Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederglobenewswire.com
Novo Nordisk A/S
Get the latest updates from Novo Nordisk A/S directly as they happen.
Follow now 37 followers
Latest posts
Last updated about 4 hours ago
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
about 4 hours ago
South San Francisco, California, US and Bagsværd, Denmark, 14 May 2025 –...
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
2 days ago
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
5 days ago
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data...
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
7 days ago
7 May 2025 - Financial report for the period 1 January 2025...
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
8 days ago
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new...
Novo Nordisk announces changes in Executive Management
about 1 month ago
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following...
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
about 2 months ago
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full...
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
about 2 months ago
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
about 2 months ago
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
about 2 months ago
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
2 months ago
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results...
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
3 months ago
Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo...